https://trethera.com https://trethera.com/about https://trethera.com/about/management-team https://trethera.com/about/co-founders-and-advisors https://trethera.com/about/board-of-directors https://trethera.com/technology https://trethera.com/pipeline https://trethera.com/regulationd https://trethera.com/contact https://trethera.com/media https://trethera.com/expanded-access-policy https://trethera.com/news https://trethera.com/publications https://trethera.com/legal/privacy https://trethera.com/legal/terms https://trethera.com/legal/cookies https://trethera.com/search https://trethera.com/news/actrims-poster-presentation-ms-treatment-research https://trethera.com/news/biocom-global-conference-clinical-momentum-expansion https://trethera.com/news/bioscience-ecosystem-summit-panel-and-poster-2025 https://trethera.com/news/dose-escalation-phase-1-solid-tumors-favorable-results https://trethera.com/news/dr-larry-steinman-ms-expert-advisory-board https://trethera.com/news/dr-michael-shepard-joins-scientific-advisory-board https://trethera.com/news/enrollment-complete-phase-1-dose-escalation-solid-tumors https://trethera.com/news/fda-approval-tre-515-phase-1-solid-tumors https://trethera.com/news/fda-clearance-tre-515-healthy-volunteers-biomarkers https://trethera.com/news/fda-fast-track-tre-515-metastatic-prostate-cancer https://trethera.com/news/fda-orphan-drug-designation-tre-515-demyelinating-optic-neuritis https://trethera.com/news/fda-orphan-drug-tre-515-acute-disseminated-encephalomyelitis https://trethera.com/news/founder-dr-caius-radu-la-bioscience-summit-2022 https://trethera.com/news/invited-speaker-purine-pyrimidine-symposium https://trethera.com/news/jefferies-frank-baxter-named-special-advisor https://trethera.com/news/landmark-tre-515-solid-tumor-trial-first-patient https://trethera.com/news/late-stage-als-patient-treated-with-tre-515 https://trethera.com/news/laurent-dubois-joins-board-of-directors https://trethera.com/news/massachusetts-general-hospital-clinical-trial-collaboration-to-evaluate-tre-515-in-als-patients https://trethera.com/news/ms-treatment-poster-ana-annual-meeting https://trethera.com/news/national-cancer-institute-grant-biomarkers-phase-1 https://trethera.com/news/national-eye-institute-grant-tre-515-optic-neuritis https://trethera.com/news/niaid-grant-tre-515-lupus-advancement https://trethera.com/news/nih-funds-preclinical-development-tre-515-crohns https://trethera.com/news/nih-grant-3m-tre-515-lupus-treatment https://trethera.com/news/nih-grant-preclinical-acute-disseminated-encephalomyelitis https://trethera.com/news/nih-grant-tre-515-crohns-disease-development https://trethera.com/news/nih-grant-tre-515-kras-inhibitor-resistance-lung-cancer https://trethera.com/news/nih-grant-tre-515-radiation-prostate-cancer https://trethera.com/news/phase-1-dose-escalation-complete-therapeutic-window-safety https://trethera.com/news/phase-1-solid-tumors-dose-escalation-cohort-4 https://trethera.com/news/phase-1-solid-tumors-trial-advances-dose-after-endpoint https://trethera.com/news/poster-presentation-ccf-annual-congress-ibd https://trethera.com/news/presentation-rare-neuroimmune-disorders-symposium-annual https://trethera.com/news/prostate-cancer-poster-presentation-aacr-annual-meeting https://trethera.com/news/r-boyd-quinnell-joins-board-of-directors https://trethera.com/news/rare-autoimmune-neuro-expert-dr-greenberg-advisory-board https://trethera.com/news/rare-neurologic-expert-dr-levy-joins-advisory-board https://trethera.com/news/seed-funding-3-2m-current-investors https://trethera.com/news/seed-funding-3-8m-current-investors https://trethera.com/news/tre-515-ip-license-market-exclusivity-until-2045 https://trethera.com/news/ucla-ms-data-tre-515-mouse-models https://trethera.com/news/ucla-tre-515-controls-immune-cell-activation-ms-mice https://trethera.com/news/us-patent-filings-tre-515-exclusivity-2041 https://trethera.com/news/uspto-composition-of-matter-patent-tre-515-exclusivity-2041 https://trethera.com/news/uspto-notice-of-allowance-tre-515-structural-patent-2041 https://trethera.com/publication/18f-fac-pet-brain-leukocytes-ms-mouse-model https://trethera.com/publication/dck-augments-atm-dna-repair-radiation-resistance https://trethera.com/publication/dck-required-for-t-b-lymphocyte-development https://trethera.com/publication/molecular-imaging-lymphoid-organs-immune-activation-18f-dcyd https://trethera.com/publication/nucleoside-salvage-pathway-kinases-regulate-hematopoiesis https://trethera.com/publication/pet-probes-specific-for-deoxycytidine-kinase https://trethera.com/publication/structure-guided-dck-inhibitors-nanomolar-stability https://trethera.com/publication/targeting-deoxycytidine-kinase-improves-ms-symptoms-in-mice https://trethera.com/videos/optic-neuritis https://trethera.com/videos/waterfall